• Key Roles to Support both Technology and Business Evolvement
    Catherine Beech OBE
  • Benedict Cross

News & Views

Key Roles to Support both Technology and Business Evolvement

Feb 26 2020

Biopharmaceutical company Phoremost has announced the appointments of Dr Catherine Beech as Non-Executive Director and Dr Benedict (Ben) Cross, who has joined as Senior Director (Technology), with responsibility for directing the evolution and development of the Company’s screening platform.

Catherine has over 25 years of biotech and pharmaceutical industry experience, including leading drug development programmes in hypertension, heart failure, Parkinson’s disease and HIV. She has also worked extensively to commercialise novel technologies in the life sciences and is a scientific founder and CEO of Exonate. Catherine has a degree in medicine from the University of Birmingham and in 2008 was awarded an OBE for services to technology and innovation.

Ben is a geneticist and biotechnologist with over ten years of professional research and management experience. He joins the company from Horizon Discovery, where he established and led the company’s functional genomic screening platform over a period of six years. The screening group now executes hundreds of screens per year, generating multi-million-pound revenue. Ben completed his PhD at the University of Manchester, with postdoctoral training at the University of Cambridge.

Dr Chris Torrance, CEO, PhoreMost, said: “We welcome both Ben and Catherine to the PhoreMost team at this exciting point in the Company’s development. We very much look forward to working with Ben to maximise the potential of the SITESEEKER platform and to the addition of Catherine’s valuable experience and guidance on the Board of Directors.”

Dr Catherine Beech, OBE, Non-Executive Director, PhoreMost, said: “I am absolutely delighted to join the Board of PhoreMost. I believe the Company is poised for success, and that 2020 will be a tremendous year on many fronts.”

Dr Ben Cross Senior Director (Technology), PhoreMost, commented: “I am excited to have been given this opportunity to work with PhoreMost and the SITESEEKER platform, which has huge potential to uncover not only previously undruggable targets, but also druggable pockets within those targets. I am very much looking forward to working with the team to drive this forward.”


Digital Edition

ILM 49.5 July

July 2024

Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...

View all digital editions

Events

ADLM 2024

Jul 28 2024 San Diego, CA USA

InaLab 2024

Jul 30 2024 Jakarta, Indonesia

Miconex

Jul 31 2024 Chengdu, China

ACS National Meeting - Fall 2024

Aug 18 2024 Denver, CO, USA

EMC2024

Aug 25 2024 Copenhagen, Denmark

View all events